Predicting Response to Intravenous Immunoglobulin in Lower Motor Neuron Syndromes

Abstract

Objective: In patients presenting with purely lower motor neuron (LMN) syndromes, the distinction between motor neuropathy and an anterior horn cell disorders may be difficult to appreciate initially. As such, the selection of patients for treatment with intravenous immunoglobulin (IVIg) is often a clinical dilemma, particularly as IVIg is an expensive, limited resource, ideally reserved for treatable patients. Consequently, the present study was undertaken to identify clinical and neurophysiological features that may predict a response to IVIg in patients presenting with pure LMN syndromes.